Dasatrue 50mg Tablet

Product Introduction

Dasatrue 50mg Tablet is an antineoplastic (anti-cancer) medication primarily used in the treatment of specific types of leukemia, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It contains the active ingredient dasatinib, which is classified as a tyrosine kinase inhibitor (TKI). This medication works by blocking the action of an abnormal protein that signals cancer cells to multiply, thereby slowing or stopping the spread of cancer cells.

Dasatrue 50mg is a film-coated tablet intended for oral administration and should be taken under the guidance and supervision of a healthcare professional. The dosage and treatment duration depend on various factors, including the type and stage of leukemia, the patient’s overall health, and their response to the therapy.

Uses of Dasatrue 50mg Tablet

Dasatrue 50mg Tablet is primarily prescribed for the following conditions:

• Chronic Myeloid Leukemia (CML): Dasatinib is used in the treatment of chronic myeloid leukemia in adults. CML is a type of cancer that starts in certain blood-forming cells of the bone marrow. Dasatrue 50mg is especially effective in patients who are resistant or intolerant to prior therapy including imatinib.
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): This form of acute lymphoblastic leukemia is characterized by the presence of the Philadelphia chromosome. Dasatinib, the active component of Dasatrue, is used as part of the treatment regimen for Ph+ ALL in adults, often when other treatments have not been successful.

Benefits of Dasatrue 50mg Tablet

Dasatrue 50mg Tablet offers several significant benefits for patients undergoing treatment for CML and Ph+ ALL:

• Targeted Therapy: Dasatrue specifically targets and inhibits the BCR-ABL tyrosine kinase, which is the abnormal protein responsible for the uncontrolled growth of cancer cells in CML and Ph+ ALL. This targeted approach helps in effectively managing the disease with potentially fewer side effects compared to conventional chemotherapy.
• Improved Survival Rates: Clinical studies have demonstrated that dasatinib significantly improves survival rates in patients with CML and Ph+ ALL. It has shown efficacy in reducing the proliferation of leukemic cells and inducing remission in a considerable percentage of patients.
• Treatment for Resistant Cases: For patients who have developed resistance or intolerance to imatinib, Dasatrue offers a viable alternative. It provides hope for those who have limited options due to the failure of prior treatments.
• Convenient Administration: Being an oral tablet, Dasatrue offers the convenience of at-home administration, reducing the need for frequent hospital visits for intravenous chemotherapy sessions. This aspect significantly improves the quality of life for patients.

Side Effects of Dasatrue 50mg Tablet

While Dasatrue 50mg Tablet is effective in treating specific leukemias, it is associated with a range of side effects, which can vary in severity from patient to patient. Common and serious side effects include:

• Common Side Effects:
  • Myelosuppression: A decrease in bone marrow activity leading to reduced production of blood cells, which can result in anemia, increased risk of infections, and easy bruising or bleeding.
  • Gastrointestinal Issues: Patients may experience nausea, vomiting, diarrhea, and abdominal pain. Managing these side effects is crucial for maintaining overall health during treatment.
  • Fluid Retention: Symptoms such as swelling in the hands, ankles, or feet, and shortness of breath can occur due to fluid retention.
  • Skin Reactions: Rash, itching, and other skin irritations are relatively common.
  • Fatigue: A significant number of patients report feeling unusually tired or weak.
• Serious Side Effects:
  • Cardiovascular Effects: Dasatinib can cause serious heart-related issues, including heart failure, arrhythmias, and a prolonged QT interval, which can be life-threatening. Regular monitoring of heart function is essential.
  • Pulmonary Arterial Hypertension (PAH): A rare but severe condition where there is high blood pressure in the arteries of the lungs. Symptoms include shortness of breath and fatigue.
  • Bleeding Disorders: Severe bleeding, particularly gastrointestinal and intracranial bleeding, has been reported. Patients should be monitored for signs of bleeding and receive prompt medical attention if they occur.
  • Infections: Due to myelosuppression, there is an increased risk of infections. Patients should be vigilant for signs of infection such as fever and seek immediate medical help.

References